5/23/2022 7:07:25 AM
AstraZeneca Aims To Transform Cancer Care With Practice-changing Data At ASCO 2022
5/23/2022 3:54:58 AM
AstraZeneca's Covid-19 Vaccine Vaxzevria Gets EU Approval As Third Dose Booster
5/5/2022 2:21:34 AM
AstraZeneca: Ultomiris Meets Primary Endpoint In CHAMPION-NMOSD Phase 3 Trial In Neuromyelitis Optica Spectrum Disorder
5/5/2022 2:16:11 AM
AstraZeneca: Enhertu Approved In US For Unresectable Or Metastatic HER2-positive Breast Cancer In Adults
5/5/2022 2:15:05 AM
AstraZeneca Says Farxiga Meets Primary Endpoint In DELIVER Phase III Trial
5/4/2022 2:12:01 AM
AstraZeneca Says Imfinzi Plus Chemotherapy Granted Priority Review In US For Biliary Tract Cancer
4/29/2022 2:10:35 AM
AstraZeneca Plans For New Strategic R&D Centre And Alexion Headquarters In Cambridge, Massachusetts
4/29/2022 2:06:56 AM
AstraZeneca PLC Q1 Reported EPS $0.25; Core EPS $1.89
4/29/2022 1:04:44 AM
Innate : First Patient Dosed In Monalizumab Phase 3 Lung Cancer Trial Triggers $50 Mln Payment From AstraZeneca
4/28/2022 2:19:51 AM
AstraZeneca Says Ultomiris Approved In The US For Adults With Generalised Myasthenia Gravis